German radiotheranostics company Navigo Proteins has entered a strategic research collaboration with SCK CEN, a Belgian nuclear research center.
The partnership will focus on the preclinical development of next-generation radiotheranostics cancer treatments using the radioisotope terbium-161 (Tb-161). Navigo has developed carrier molecules, while SCK CEN provides Tb-161, infrastructure, and expertise in preclinical testing.
The collaboration will focus on preclinical studies of multiple undisclosed targets, with researchers testing whether the molecules successfully deliver the radioactivity to tumors and assess their efficiency. The aim is to identify a promising candidate within two to three years and prepare all necessary data to initiate clinical studies, the companies said.
